Company profile
Amphista Therapeutics Developing novel medicines through next generation protein degradation
Amphista Therapeutics Limited is a UK company with status active founded in 2017 based in East of England.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Amphista Therapeutics develops pharmaceuticals that are designed to use targeted protein degradation to hijack and suppress cell's responsible for disease progression.
Amphista is a biotech company based around PROTAC technology. Proteolysis targeting chimeras (PROTACs) are an alternative to traditional small molecules as a therapeutic approach to inhibiting disease causing proteins.
Amphista Therapeutics is a University of Dundee spin off company that is developing targeted protein degradation platforms
The company was incorporated in December 2017 with investment from Advent Life Sciences
commercial in confidence
